NCT04895020View on ClinicalTrials.gov

Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years

PHASE3RecruitingINTERVENTIONAL
Enrollment

1,200

Participants

Timeline

Start Date

May 28, 2021

Primary Completion Date

January 13, 2023

Study Completion Date

May 31, 2026

Conditions
HPV InfectionsCervical CancerVulvar CancerVaginal CancerCIN1CIN2CIN 3VaIN1VaIN2VaIN3Genital WartVIN 1VIN 2VIN 3AIS
Interventions
BIOLOGICAL

9-valent HPV vaccine

9-valent HPV recombinant vaccine (Hansenula Polymorpha) All subjects aged 9 to 45 years received 3 doses of 9v HPV vaccine at 0,2,6 month scehdule

Trial Locations (1)

Unknown

RECRUITING

Huakun Lv, Hangzhou

All Listed Sponsors
collaborator

Chongqing Bovax Biopharmaceutical Co., Ltd.

INDUSTRY

lead

Shanghai Bovax Biotechnology Co., Ltd.

INDUSTRY